Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Radiation plus antiandrogen therapy improves prostate cancer survival, suggests research

Men with localised prostate cancer do better with radiotherapy combined with androgen deprivation treatment than with radiotherapy alone, suggest research findings presented at the European Society for Radiotherapy and Oncology 33rd annual congress in Vienna, Austria, today (7 April 2014).

Prostate cancer cells

Source: Paul Hakimata / Dreamstime.com

Combination treatment was significantly better than radiotherapy alone in terms of clinical progression-free survival for men with prostate cancer

Michael Bolla, the study’s lead author, from Grenoble University Hospital, France, said that the findings would be expected to change clinical practice. “During multidisciplinary team meetings to discuss a patient’s treatment, this combined treatment approach should be one of the options proposed for men with localised prostate cancer that has an intermediate or high risk of growing and spreading,” he said.

Advertisement

The trial involved 819 men in 14 countries with intermediate- or high-risk localised prostate cancer. They were randomly assigned to receive three-dimensional conformal radiotherapy with or without androgen deprivation therapy. This comprised two injections, given three months apart, of a luteinising hormone–releasing hormone analogue, plus the oral antiandrogen bicalutamide for 15 days. 

After a median follow-up of 7.2 years, radiotherapy plus hormone therapy was significantly better than radiotherapy alone for the endpoints of biochemical progression-free survival and clinical progression-free survival, with hazard ratios of 0.53 (0.42–0.67; P<0.001) and 0.63 (0.48–0.84; P=0.001), respectively.

In terms of toxicity, severe impairment of sexual function was significantly more frequent with combination therapy, at 27.0 per cent versus 19.4 per cent for radiotherapy alone.

“Although we need longer follow-up to assess the impact on these men’s overall survival, these findings need to be taken into account in daily clinical practice,” Professor Bolla remarked.

Citation: The Pharmaceutical JournalURI: 11137062

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save

Newsletter Sign-up

Get the latest emails sent to your inbox.